EUVIMEDEUVIMED entdecken
Crossref

Postoperative Human Papilloma Virus Circulating Tumor DNA Guided Adjuvant Therapy for Human Papilloma Virus-Related Oropharyngeal Carcinoma (PATH Study)

Linda Chen, Marc Cohen, Vaios Hatzglou, Zhigang Zhang, Nadeem Riaz, Achraf A Shamseddine, Luc G T Morris, Sean M McBride, Daphna Y Gelblum, Kaveh Zakeri, Yao Yu, Ian Ganly und 15 weitere

International Journal of Radiation Oncology*Biology*Physics · 2026

DOI: 10.1016/j.ijrobp.2025.09.044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026. Verfasst von Linda Chen und 26 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: chenl1@uchicago.edu. Hauptthemen laut MEDLINE: Oropharyngeal Neoplasms, Circulating Tumor DNA, DNA, Viral, Papillomavirus Infections. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: James and Judith K Dimon Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Human papillomavirus (HPV) circulating tumor DNA (ctDNA) is a biomarker which detects minimal residual disease for HPV-associated oropharyngeal carcinoma (OPC) (HPV+ OPC). We conducted the first prospective study using HPV ctDNA as an integral biomarker to select patients for postoperative radiation therapy omission. We tested the hypothesis that undetectable postoperative HPV ctDNA can be used to omit or delay adjuvant radiation until patients develop detectable HPV ctDNA using the NavDx (Naveris, Inc) tumor tissue-modified viral (TTMV) HPV DNA score. Eligible HPV+ OPC patients had a preoperative TTMV-HPV DNA score of ³50 and at least 1 pathologic risk factor to warrant standard adjuvant radiation therapy. METHODS AND MATERIALS: Postoperatively, eligible patients had no evidence of disease on postoperative magnetic resonance imaging and 2 negative TTMV-HPV DNA test results. Patients with non-HPV-16 genotype, positive margins, and extranodal extension were excluded. Patients were monitored with TTMV-HPV DNA testing, imaging, and physical exams. Delayed adjuvant radiation was initiated if patients developed detectable TTMV-HPV DNA without radiographic recurrence. The primary endpoint was the proportion of patients without gross recurrent disease. RESULTS: Fifty-five HPV+ OPC patients were screened; 12 patients were enrolled. The median follow-up was 26.6 months (range, 18.3-40.3). One patient (8%) developed detectable HPV ctDNA 6 months after surgery without evidence of recurrence and was treated with delayed adjuvant radiation therapy. Three additional patients (25%) developed radiographic recurrence 6 months after surgery. Radiographic recurrence was not preceded by detectable TTMV-HPV DNA. TTMV-HPV DNA detection was synchronous with radiographically evident disease in 2 of 3 patients. Recurrence was associated with N2b disease pretreatment (P = .01). The high gross recurrence rate (3 of 12 patients) led to closure of this cohort due to a prespecified stopping rule. CONCLUSIONS: Deferring adjuvant radiation therapy based on HPV ctDNA using NavDx TTMV-HPV DNA testing resulted in a high rate of disease recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oropharyngeal NeoplasmsCirculating Tumor DNADNA, ViralPapillomavirus InfectionsPapillomaviridaeHumansMaleFemaleMiddle AgedAgedProspective StudiesRadiotherapy, AdjuvantNeoplasm, ResidualAdultAged, 80 and overPostoperative PeriodBiomarkers, TumorHuman Papillomavirus Viruses

Substanzen

Circulating Tumor DNADNA, ViralBiomarkers, Tumor

Autor:innen und Institutionen

  • Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: chenl1@uchicago.edu.
  • Departments of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Departments of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Departments of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Radiation Oncology, Baptist Health Miami Cancer Institute, Miami, Florida.

Förderung

  • James and Judith K Dimon Foundation

Zitieren

APA

Chen, L., Cohen, M., Hatzglou, V., Zhang, Z., Riaz, N., Shamseddine, A. A., Morris, L. G. T., McBride, S. M., Gelblum, D. Y., Zakeri, K., Yu, Y., Ganly, I., Cracchiolo, J., Wong, R. J., Kalman, N. S., Tassler, A. B., Kutler, D., Wong, W., Kriplani, A., …, & Lee, N. Y. (2026). Postoperative Human Papilloma Virus Circulating Tumor DNA Guided Adjuvant Therapy for Human Papilloma Virus-Related Oropharyngeal Carcinoma (PATH Study). International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2025.09.044

Vancouver

Chen L, Cohen M, Hatzglou V, Zhang Z, Riaz N, Shamseddine AA, et al. Postoperative Human Papilloma Virus Circulating Tumor DNA Guided Adjuvant Therapy for Human Papilloma Virus-Related Oropharyngeal Carcinoma (PATH Study). International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2025.09.044

BibTeX
@article{Chen2026,
  author = {Chen, Linda and Cohen, Marc and Hatzglou, Vaios and Zhang, Zhigang and Riaz, Nadeem and Shamseddine, Achraf A and Morris, Luc G T and McBride, Sean M and Gelblum, Daphna Y and Zakeri, Kaveh and Yu, Yao and Ganly, Ian and Cracchiolo, Jennifer and Wong, Richard J and Kalman, Noah S and Tassler, Andrew B and Kutler, David and Wong, Winston and Kriplani, Anuja and Dunn, Lara and Ho, Alan L and Michel, Loren S and Fetten, James and Pfister, David G and Katabi, Nora and Sherman, Eric J and Lee, Nancy Y},
  title = {Postoperative Human Papilloma Virus Circulating Tumor DNA Guided Adjuvant Therapy for Human Papilloma Virus-Related Oropharyngeal Carcinoma (PATH Study)},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2026},
  doi = {10.1016/j.ijrobp.2025.09.044}
}
Kostenlos starten →